These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

875 related items for PubMed ID: 11341502

  • 1. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
    Colucci M, D'Aprile AM, Italia A, Gresele P, Morser J, Semeraro N.
    Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
    [Abstract] [Full Text] [Related]

  • 2. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
    Guimarães AH, Rijken DC.
    Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
    [Abstract] [Full Text] [Related]

  • 3. Effect of heparin on TAFI-dependent inhibition of fibrinolysis: relative importance of TAFIa generated by clot-bound and fluid phase thrombin.
    Colucci M, Pentimone A, Binetti BM, Cramarossa M, Piro D, Semeraro N.
    Thromb Haemost; 2002 Aug; 88(2):282-7. PubMed ID: 12195701
    [Abstract] [Full Text] [Related]

  • 4. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
    Semeraro F, Piro D, Rossiello MR, Ammollo T, Colucci M.
    Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
    [Abstract] [Full Text] [Related]

  • 5. Antithrombotic effects due to pharmacological modulation of thrombin-activatable fibrinolysis inhibitor in rats.
    Soni H, Sharma A, Bhatt S, Jain MR, Patel PR.
    Pharmacology; 2008 Dec; 82(4):304-9. PubMed ID: 18936552
    [Abstract] [Full Text] [Related]

  • 6. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
    Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, Gresele P.
    Hepatology; 2003 Jul; 38(1):230-7. PubMed ID: 12830006
    [Abstract] [Full Text] [Related]

  • 7. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M, Scopece S, Gelato AV, Dimonte D, Semeraro N.
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [Abstract] [Full Text] [Related]

  • 8. Fibrinolytic efficacy of Amediplase, Tenecteplase and scu-PA in different external plasma clot lysis models: sensitivity to the inhibitory action of thrombin activatable fibrinolysis inhibitor (TAFI).
    Guimarães AH, Barrett-Bergshoeff MM, Criscuoli M, Evangelista S, Rijken DC.
    Thromb Haemost; 2006 Sep; 96(3):325-30. PubMed ID: 16953274
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Contact activation prolongs clot lysis time in human plasma: role of thrombin-activatable fibrinolysis inhibitor and Factor XIII.
    Nielsen VG, Steenwyk BL, Gurley WQ.
    J Heart Lung Transplant; 2006 Oct; 25(10):1247-52. PubMed ID: 17045938
    [Abstract] [Full Text] [Related]

  • 11. [The TAFI system. The new role of fibrinolysis].
    Dempfle CE.
    Hamostaseologie; 2007 Sep; 27(4):278-81. PubMed ID: 17938767
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of concomitant thrombin-mediated fibrin formation enhances clot lysis in whole blood.
    Haskel EJ, Eisenberg PR, Abendschein DR.
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):7-13. PubMed ID: 8457655
    [Abstract] [Full Text] [Related]

  • 13. Quantification of the effects of thrombin activatable fibrinolysis inhibitor and alpha2-antiplasmin on fibrinolysis in normal human plasma.
    Nielsen VG, Ellis TC.
    Blood Coagul Fibrinolysis; 2007 Jan; 18(1):29-33. PubMed ID: 17179823
    [Abstract] [Full Text] [Related]

  • 14. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N, Guldiken S, Demir M, Tugrul A.
    Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
    [Abstract] [Full Text] [Related]

  • 15. Clot structure modification by fondaparinux and consequence on fibrinolysis: a new mechanism of antithrombotic activity.
    Varin R, Mirshahi S, Mirshahi P, Kierzek G, Sebaoun D, Mishal Z, Vannier JP, Yvonne Borg J, Simoneau G, Soria C, Soria J.
    Thromb Haemost; 2007 Jan; 97(1):27-31. PubMed ID: 17200767
    [Abstract] [Full Text] [Related]

  • 16. The role of protein S in the activation of thrombin activatable fibrinolysis inhibitor (TAFI) and regulation of fibrinolysis.
    Mosnier LO, Meijers JC, Bouma BN.
    Thromb Haemost; 2001 Oct; 86(4):1040-6. PubMed ID: 11686322
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma.
    Kim PY, Foley J, Hsu G, Kim PY, Nesheim ME.
    Anal Biochem; 2008 Jan 01; 372(1):32-40. PubMed ID: 17967438
    [Abstract] [Full Text] [Related]

  • 19. Thrombin activatable fibrinolysis inhibitor (TAFI): a role in pre-eclampsia?
    Dusse LM, Cooper AJ, Lwaleed BA.
    Clin Chim Acta; 2007 Mar 01; 378(1-2):1-6. PubMed ID: 17184758
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.